Mild Renal Impairment

  • Legend
    • initiation-dosing-symbol

      Initiation Doses

    • maintenace-dose-symbol

      Maintenance Doses

    • legend-pp1m-plasma-concentration

      Cumulative INVEGA SUSTENNA® Plasma Concentration

    • legend-pp3m-plasma-concentration

      Cumulative INVEGA TRINZA® Plasma Concentration

    • legend-er-plasma-concentration

      Cumulative Oral INVEGA® ER Plasma Concentration

    • legend-er-doses

      Daily Oral INVEGA® Doses

    • legend-rl-dose-symbol

      Cumulative RISPERDAL CONSTA® Plasma Concentration

    • median-plasma-concentration-symbol

      Median Plasma Concentration for Oral INVEGA® ER 6-12 mg/day

    • initiation-dosing-symbol

      Initiation Doses

    • maintenace-dose-symbol

      Maintenance Doses

    • legend-old-browser-paliperidone-palmitate-concentration

      Cumulative Paliperidone Palmitate Concentration

    • legend-er-doses

      Daily Oral INVEGA® ER Dose

    • legend-rl-dose-symbol-greyscale

      Cumulative RISPERDAL CONSTA® Plasma Concentration

    • Week 1 = Day 8

  • Zoom:

Make A Dose Change

×

Apply to This Dose

Apply to All Future Doses

Typical Paliperidone Plasma Concentration (ng/mL)
Typical Paliperidone Plasma Concentration (ng/mL)
Dose Information

Graph Information

^ Back to Top

Transitioning a Patient with Mild Renal Impairment to INVEGA TRINZA®

Consistent with the INVEGA TRINZA® Prescribing Information:

  • INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® has been established as adequate treatment for at least four months.
  • In order to establish a consistent maintenance dose, it is recommended that the last two doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®.
  • INVEGA TRINZA® has not been systematically studied in patients with renal impairment. INVEGA TRINZA® is not recommended in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min).
  • For patients with mild renal impairment (creatinine clearance ≥50 mL/min to <80 mL/min [Cockcroft-Gault Formula], adjust dosage and stabilize the patient using INVEGA SUSTENNA®, then transition to INVEGA TRINZA® using the equivalent 3.5-fold higher dose as shown in the table below.
  • While the INVEGA TRINZA® Prescribing Information does permit a dosing window to avoid a first INVEGA TRINZA® missed dose, in this scenario, the timing of the first INVEGA TRINZA® dose is locked and cannot be adjusted ±7 days.

INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®

If the Last Dose of INVEGA SUSTENNA® is:

Initiate INVEGA TRINZA® at the Following Dose:

78 mg

273 mg

117 mg

410 mg

156 mg

546 mg

234 mg

819 mg

Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.

  • INVEGA TRINZA® should be administered every 3 months.
  • Administration: For intramuscular injection only by a healthcare professional. Care should be taken to avoid inadvertent injection into a blood vessel.

INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:

INVEGA SUSTENNA® for:

  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

INVEGA TRINZA® for:

  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm

×

Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel